CTRI/2015/03/005653招募中未知
A randomized, open label, multi centric, two treatment, two period, two sequence, single dose, crossover, bioequivalence study of Paclitaxel protein-bound particles for injectable suspension (albumin-bound) 100 mg/vial manufactured by Sindan Pharma for Actavis LLC, USA and Abraxane 100 mg/vial (Albumin bound Paclitaxel 260 mg/m2) intravenous infusion Abraxis BioScience LLC, New Jersey in patients with metastatic breast cancer
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- Actavis LLC
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •i. Female patients aged between 18 - 60 years of age (inclusive) with histological or cytological confirmation of diagnosis of breast cancer.
- •ii.Female patients with metastatic breast cancer (No known CNS metastasis) after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. If the patient is already receiving Paclitaxel, at least two more cycles of Paclitaxel should be required for completing the course of chemotherapy, for inclusion in the study.
- •iii. Life expectancy of more than 6 months as judged by the Investigator.
- •iv. ECOG (Eastern Cooperative Oncology Group) performance status of 2 or less.
- •v. Adequate renal function defined as Serum Creatinine <=1.5 times ULN
- •vi. Previous chemotherapy and or radiotherapy should be completed 4 weeks prior to start of first IMP administration for the current study
- •vii. Previous hormonal treatment should be completely washed out prior to start of IMP administration
- •viii. Satisfactory medical assessment done by investigator to ensure that there are no clinically significant and relevant abnormalities (of medical history, physical examination and ECG, clinical or laboratory evaluation (haematology, biochemistry, serology and urinalysis). Patients must have Hemoglobin >= 9 gm/dl for inclusion in the study
- •ix. Postmenopausal women with amenorrhea for at least 12 consecutive months
- •x. Female patients of child bearing potential must agree to use one of the following contraceptive measures during and for at least three months after cessation of therapy:
- •a. Surgically sterile (bilateral tubal ligation, hysterectomy, bilateral oophorectomy).
- •b. IUD in place for at least 3 months.
- •c. Barrier methods (condom, diaphragm) with spermicide for at least 14 days prior to the first dose, throughout the study and for 4 days following the last dose.
- •d. Abstinence
- •e. Other birth control methods deemed acceptable by the investigator
- •xi. The patient must understand and be able, willing and likely to fully comply with study procedures and restrictions
- •xii. Patient must have provided signed and dated Informed consent given in written form in accordance with the International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) Guideline E6 and applicable regulations, before initiating any study-related procedures
排除标准
- •i. History or presence of significant current or recurrent disease (other than breast cancer) that could affect the action or disposition of the investigational product, or clinical or laboratory assessments.
- •ii. History or presence of significant current or relevant previous history of serious, severe or unstable (acute or progressive) physical or psychiatric illness, any medical disorder that may require treatment (other than breast cancer) or make the patient unlikely to fully complete the study, or any condition that presents undue risk from the investigational product or procedures.
- •iii. Patients requiring any concurrent chemotherapy, hormonal therapy, immunotherapy, therapy with biologicals or radiotherapy for the disease.
- •iv. Patients with medical conditions that preclude administration of chemotherapy [uncontrolled intercurrent illness like unstable angina, myocardial infarction (within 6 months prior to study entry), congestive heart failure, serious cardiac arrhythmias, uncontrolled diabetes, autoimmune disease, or any uncontrolled systemic disease (e.g. recurrent pleural effusion / ascites, active infections, patients with immune deficiency disorders) or patients already on immunosuppressive drugs] or any other significant co-morbid conditions as determined by the investigator (s).
- •v. Patients with liver impairment - serum transaminase levels (alanine transaminase [ALT] and/or aspartate transaminase [AST]) greater than 2.5 times the upper limit of normal (ULN) concurrent with serum alkaline phosphatase levels greater than 2.5 times the ULN
- •vi. Patients with absolute neutrophil count of < 1,500 cells/mm3 & platelet < 1,00,000 /mm3 during screening
- •vii. Serum albumin < 3 gm/dl
- •viii. Presence of Left ventricular ejection fraction (LVEF) of <50% as determined by Echocardiography (ECHO)/ Multiple Gated Acquisition scan (MUGA).
- •ix. Previous documented history of QTc prolongation with other medication or patient with congenital QT prolongation or patient with Patients with QTc >= 470 ms (where QTc based on Bazettâ??s correction method) or patient with any other significant cardiac disease.
- •x. Presence of left bundle branch block (LBBB) and with significant atrioventricular block (AV block).
- •xi. Current (within 2 weeks of the start of the study) or regular use of any medication (including over the counter [OTC], herbal or homeopathic preparations) that could affect (improve or worsen) the condition being studied, or could affect the action, absorption or disposition of the investigational product, or clinical or laboratory assessment.
- •xii. Clinical illness other than breast cancer, radiotherapy or any major surgery within 4 weeks before the start of the study.
- •xiii. Patients with known CNS metastasis.
- •xiv. Positive urine drug screening, HIV, VDRL/RPR, Hepatitis B & C tests.
- •xv. Patients with severe fluid retention e.g. pleural effusion, pericardial effusion or ascites.
- •xvi. Patients previously been randomized into this study and subsequently withdrawn
- •xvii. Known or suspected intolerance or Hypersensitivity to Paclitaxel or any of the excipients or any other taxane
- •xviii. Patients who have participated in any other clinical study in the preceding 30 days prior to the start of the study.
- •xix. Patients who are pregnant or demonstrating a positive pregnancy screen or are currently breast-feeding or pl
研究者
相似试验
进行中（未招募）
不适用
Bioequivalence (BE) study of Paclitaxel 100mg/vial with ABRAXANE® 100mg/vial in subject with metastatic Breast cancer after failure of combination chemotherapy or relapse within 6 months of adjuvant chemotherapy.CTRI/2024/03/064383Anbison Lab. Co., Ltd.
尚未招募
不适用
Bioequivalence study of doxorubicin hydrochloride liposome injection 2mg/mL in ovarian cancer subjects under fasting conditions.CTRI/2020/05/025245Shanghai Jingfeng Pharmaceuticals Group Co Ltd China
招募中
不适用
Bioequivalence Study of Leuprolide Depot Injection 7.5 mg of with LUPRON Depot (leuprolide acetate for depot suspension) 7.5 mg in subjects with locally advanced and/or metastatic prostate cancer undergoing initial therapy.CTRI/2022/04/041602American Regent Inc
招募中
不适用
A clinical study to assess the comparative blood concentration of two anti-cancer drugs (test and marketed Paclitaxel) in patients with breast cancerCTRI/2018/08/015506Teva Pharmaceuticals USA
已完成
不适用
A study to evaluate the safety of Doxorubicin from Panacea Biotech Ltd (test drug) in comparison to the Doxorubicin of Sun Pharmaceuticals Ind. Ltd. (reference drug) in ovarion cancer patientsCTRI/2017/03/008179Panacea Biotech Ltd32